- Company
- Trulicity's share reaches 99.8%
- by Kim, Jin-Gu Aug 28, 2023 05:21am
- Trulicity, a GLP-1 analog class diabetes treatment, once again set the record for highest sales. However, it is unclear whether this upward trend will continue in the second half. This is because it is said that some disruptions have occurred in domestic supply due to a shortage of global distribution supplies. Ozempic and Rybelsus, which ar
- Company
- Discussion on expanding coverage for Leclaza begins
- by Eo, Yun-Ho Aug 28, 2023 05:21am
- Attention is focused on expanding insurance coverage for the first-line treatment of the anticancer drug Leclaza. According to related industries, Yuhan Corporation's 3rd generation EGFR TKI Leclaza will be scheduled for the HIRA on the 30th. The specific indication is 'primary treatment for EGFR active non-small cell lung cancer'. Leclaza o
- Company
- New drug Shingrix leads shingles vaccine mkt
- by Chon, Seung-Hyun Aug 28, 2023 05:21am
- GlaxoSmithKline's shingles vaccine 'Shingrix' took the lead in Korea’s market just 7 months after its release. With its powerful shingles prevention effect, its sales surpassed that of its competitors. SkYZoster, a homegrown vaccine, had taken the lead in the market for the first time at the end of last year but was overtaken by Shingrix in jus
- Company
- Hanmi Pharm starts P1T on its next-gen immuno-oncology drug
- by Chon, Seung-Hyun Aug 25, 2023 06:06am
- On the 22nd, Hanmi Pharm announced that it has recently received approval to initiate a domestic Phase I trial for its next-generation immuno-oncology drug ‘‘BH3120(PD-L1/4-1BB BsAb)’ from the Ministry of Food and Drug Safety. In May, the company had previously received approval from the US FDA for the same drug candidate after submitting an
- Policy
- Are there any countermeasures against Rx of hair loss pills?
- by Lee, Jeong-Hwan Aug 25, 2023 06:06am
- The Health and Welfare Committee of the National Assembly will start reviewing legislation to institutionalize non-face-to-face treatment, excluding the prescription restriction bill for high-risk non-insured drugs such as hair loss treatment, which is being prepared by Rep. Jeon Hye-sook, and the public e-prescription legislation proposed by
- Policy
- Bayer completes pricing negotiations for Jivi Inj in KOR
- by Lee, Tak-Sun Aug 25, 2023 06:06am
- Bayer’s s hemophilia A treatment ‘Jivi Inj (damoctocog alfa pegol)’ has come one step near to receiving reimbursement in Korea. On the other hand, reimbursement discussions for Lilly Korea’s ‘Retevmo (selpercatinib)’ have returned to square one after the company failed to complete pricing negotiations for its RET targeted anticance
- Policy
- Reduction in the scope of platform regulation & re-examinati
- by Lee, Jeong-Hwan Aug 25, 2023 06:06am
- Following the decision to postpone the non-face-to-face treatment institutionalization bill again by the National Assembly Health and Welfare Committee on the 24th, it is evaluated that the number of issues to be resolved for legislation has increased. At the same time, the need to reduce the scope of non-face-to-face treatment patients comp
- Company
- Company Roche and Drug Keytruda will lead industry in 5 yrs
- by Kim, Jin-Gu Aug 25, 2023 06:06am
- A projection has been made that Roche will become the top global-grossing pharmaceutical company 5 years from now in 2028. Evaluate, the global pharmaceutical market analysis institution that released such projections, also predicted that Keytruda would take over Humira’s throne and become the No. 1 grossing drug among pharmaceuticals. On th
- Product
- Hugel’s 'Licellvi Webinar' Successfully Completed
- by 어윤호 Aug 24, 2023 09:00am
- Hugel held a webinar for Thai healthcare professionals (HCPs) on Licellvi (Product name in Korea - Blue Rose Forte). The topic of the webinar was the "Combination of Thread Lifting and Botulinum Toxin", which was attended by over 300 local HCPs. The first speaker, Dr Choi Hosung (Piena Clinic), presented "Exploring the Mid & Lower Face
- Opinion
- [Reporter's view] Hemophilia drug war of nerves
- by Kim, Jin-Gu Aug 24, 2023 05:46am
- GC Pharma snipes JW Pharmaceutical. Hemlibra, a hemophilia treatment that JW Pharmaceutical is introducing and selling in Korea, became the target. GC Pharma distributed a press release on the 21st. It is a press release titled, 'The report rate of abnormal blood clots in Hemlibra was 2.8 times higher than Factor XIII.' This press release
